Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2024 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.22/25399 |
Resumo: | While biosimilar medicines can contribute to the sustainability of healthcare systems, their utilization rate varies across European countries. This study aims to identify and systematize policy measures and instruments used in European countries to increase biosimilar market share. A systematic review was conducted according to PRISMA 2020 recommendations. Medline-PubMed, Web of Science and ScienceDirect databases were searched using inclusion criteria that required full articles published in English between January 2006 and November 2023. Reviews, letters, reports, editorials and comments or opinion articles were excluded from this study. Of the 1,137 articles, only 13 met the eligibility criteria for analysis, which covered a total of 28 European countries. Pricing regulation measures were found in 27 of these countries with tendering, price-linkage and internal reference price being the most used. Tendering was used by 27 countries to procure biosimilars in inpatient setting. Prescribing guidelines and recommendations were the widely used instrument. Some European countries adopted physician incentives, quotas, and prescription by international non-proprietary name. Automatic substitution was not commonly recommended or applied. Interchangeability and switching will become increasingly relevant issues. It is important that the positive results from some countries serve as an example for the future of these medicines in the European market. |
id |
RCAP_6edd3d8e36529b9d2265b2667903013f |
---|---|
oai_identifier_str |
oai:recipp.ipp.pt:10400.22/25399 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic reviewBiological productsBiosimilar pharmaceuticalsDrug substitutionHealth policyEconomicsWhile biosimilar medicines can contribute to the sustainability of healthcare systems, their utilization rate varies across European countries. This study aims to identify and systematize policy measures and instruments used in European countries to increase biosimilar market share. A systematic review was conducted according to PRISMA 2020 recommendations. Medline-PubMed, Web of Science and ScienceDirect databases were searched using inclusion criteria that required full articles published in English between January 2006 and November 2023. Reviews, letters, reports, editorials and comments or opinion articles were excluded from this study. Of the 1,137 articles, only 13 met the eligibility criteria for analysis, which covered a total of 28 European countries. Pricing regulation measures were found in 27 of these countries with tendering, price-linkage and internal reference price being the most used. Tendering was used by 27 countries to procure biosimilars in inpatient setting. Prescribing guidelines and recommendations were the widely used instrument. Some European countries adopted physician incentives, quotas, and prescription by international non-proprietary name. Automatic substitution was not commonly recommended or applied. Interchangeability and switching will become increasingly relevant issues. It is important that the positive results from some countries serve as an example for the future of these medicines in the European market.FrontiersRepositório Científico do Instituto Politécnico do PortoMachado, Sara Cruz, AgostinhoFerreira, Pedro Lopes Morais, Carminda Pimenta, Rui2024-04-23T15:23:25Z2024-02-282024-02-28T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.22/25399engMachado, S., Cruz, A., Ferreira, P. L., Morais, C., & Pimenta, R. E. (2024). Policy measures and instruments used in European countries to increase biosimilar uptake: A systematic review. Frontiers in Public Health, 12, 1–9. https://doi.org/10.3389/fpubh.2024.12634722296-256510.3389/fpubh.2024.1263472info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-01T01:46:09Zoai:recipp.ipp.pt:10400.22/25399Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-01T01:46:09Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review |
title |
Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review |
spellingShingle |
Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review Machado, Sara Biological products Biosimilar pharmaceuticals Drug substitution Health policy Economics |
title_short |
Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review |
title_full |
Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review |
title_fullStr |
Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review |
title_full_unstemmed |
Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review |
title_sort |
Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review |
author |
Machado, Sara |
author_facet |
Machado, Sara Cruz, Agostinho Ferreira, Pedro Lopes Morais, Carminda Pimenta, Rui |
author_role |
author |
author2 |
Cruz, Agostinho Ferreira, Pedro Lopes Morais, Carminda Pimenta, Rui |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Politécnico do Porto |
dc.contributor.author.fl_str_mv |
Machado, Sara Cruz, Agostinho Ferreira, Pedro Lopes Morais, Carminda Pimenta, Rui |
dc.subject.por.fl_str_mv |
Biological products Biosimilar pharmaceuticals Drug substitution Health policy Economics |
topic |
Biological products Biosimilar pharmaceuticals Drug substitution Health policy Economics |
description |
While biosimilar medicines can contribute to the sustainability of healthcare systems, their utilization rate varies across European countries. This study aims to identify and systematize policy measures and instruments used in European countries to increase biosimilar market share. A systematic review was conducted according to PRISMA 2020 recommendations. Medline-PubMed, Web of Science and ScienceDirect databases were searched using inclusion criteria that required full articles published in English between January 2006 and November 2023. Reviews, letters, reports, editorials and comments or opinion articles were excluded from this study. Of the 1,137 articles, only 13 met the eligibility criteria for analysis, which covered a total of 28 European countries. Pricing regulation measures were found in 27 of these countries with tendering, price-linkage and internal reference price being the most used. Tendering was used by 27 countries to procure biosimilars in inpatient setting. Prescribing guidelines and recommendations were the widely used instrument. Some European countries adopted physician incentives, quotas, and prescription by international non-proprietary name. Automatic substitution was not commonly recommended or applied. Interchangeability and switching will become increasingly relevant issues. It is important that the positive results from some countries serve as an example for the future of these medicines in the European market. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-04-23T15:23:25Z 2024-02-28 2024-02-28T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.22/25399 |
url |
http://hdl.handle.net/10400.22/25399 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Machado, S., Cruz, A., Ferreira, P. L., Morais, C., & Pimenta, R. E. (2024). Policy measures and instruments used in European countries to increase biosimilar uptake: A systematic review. Frontiers in Public Health, 12, 1–9. https://doi.org/10.3389/fpubh.2024.1263472 2296-2565 10.3389/fpubh.2024.1263472 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers |
publisher.none.fl_str_mv |
Frontiers |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
_version_ |
1817543323530821632 |